While preclinical studies often focus on a single antigen, such as MOG, MBP, or PLP, MS involves dynamic antigen spreading, necessitating multiepitope strategies to achieve broad and durable immune tolerance. This evidence concerns the gene MBP and myeloid sarcoma.